Evaluating progression and quality of life in patients with age-related macular degeneration
Evaluation of Clinical Progression, Prognostic Factors, and Quality of Life in Patients with Age-related Macular Degeneration (VERA-nAMD).
This study is testing how age-related macular degeneration affects vision and quality of life in people over 50 to see what factors influence the disease's progression.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 50 Years to 120 Years |
| Sex | All |
| Sponsor | University of Udine Academic / other |
| Drugs / interventions | ranibizumab |
| Locations | 1 site (Udine, UD) |
| Trial ID | NCT06899360 on ClinicalTrials.gov |
What this trial studies
The VERA-AMD study is a prospective, observational study that aims to evaluate the clinical progression, prognostic factors, and quality of life in patients aged 50 and older with age-related macular degeneration (AMD). By analyzing real-world clinical data from 200 patients, the study seeks to identify key predictors of disease progression and functional outcomes. Primary outcomes include the rate of progression to advanced AMD and changes in visual acuity, while secondary outcomes focus on retinal morphology and quality of life assessments. The study integrates anti-VEGF therapy and AI-based fluid analysis to explore their impact on disease management.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals aged 50 and older with a confirmed diagnosis of age-related macular degeneration in at least one eye.
Not a fit: Patients with significant ocular or systemic diseases that could affect visual outcomes may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management strategies for patients with age-related macular degeneration, enhancing their quality of life and visual outcomes.
How similar studies have performed: Other studies have shown success in using observational approaches to understand AMD progression, making this study a valuable addition to existing knowledge.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * age ≥ 50 years. * confirmed diagnosis of AMD in at least one eye. * follow-up scheduled according to standard clinical practice. Exclusion Criteria: * presence of other significant ocular conditions that could affect visual acuity. * systemic conditions that make the patient unsuitable for long-term follow-up.
Where this trial is running
Udine, UD
- Department of Ophthalmology — Udine, Ud, Italy (Recruiting)
Study contacts
- Principal investigator: Daniele Veritti — Department of Ophthalmology, University of Udine
- Study coordinator: Daniele Veritti
- Email: daniele.veritti@uniud.it
- Phone: +390432559907
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.